This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis | MicrobiomeTrials
← Back to trials NCT07262983
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis Recruiting PHASE1 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-10-29Est. Completion: 2030-05-01
Enrollment target: 20 participantsLocations National Institutes of Health Clinical Center, Bethesda, Maryland, United States Other microbiome trials you might be interested in Infections Pneumonia Immune System Diseases STAT3 Transcription Factor Job Syndrome
The Hyper IgE Syndromes (HIES) are primary immunodeficiencies resulting in eczema and recurrent skin and lung infections…
Bethesda, United States
Autosomal-dominant Hyper-IgE Syndrome
Background:
AD-HIES is a disease that weakens the immune system. It puts people at risk for infections, particularly St…
Bethesda, United States Completed Jul 22, 2018